CN104602716A - 放射性药物络合物 - Google Patents

放射性药物络合物 Download PDF

Info

Publication number
CN104602716A
CN104602716A CN201380035189.1A CN201380035189A CN104602716A CN 104602716 A CN104602716 A CN 104602716A CN 201380035189 A CN201380035189 A CN 201380035189A CN 104602716 A CN104602716 A CN 104602716A
Authority
CN
China
Prior art keywords
complex
hopo
targeting moiety
moiety
thorium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380035189.1A
Other languages
English (en)
Chinese (zh)
Inventor
汉内·特蕾泽·本格-汉森
奥拉夫·本杰明·瑞安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta ASA filed Critical Algeta ASA
Publication of CN104602716A publication Critical patent/CN104602716A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
CN201380035189.1A 2012-05-11 2013-05-13 放射性药物络合物 Pending CN104602716A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes
GB1208309.3 2012-05-11
PCT/EP2013/059839 WO2013167754A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Publications (1)

Publication Number Publication Date
CN104602716A true CN104602716A (zh) 2015-05-06

Family

ID=46458687

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380036807.4A Pending CN104619355A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CN201380036905.8A Pending CN104540530A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CN201380035189.1A Pending CN104602716A (zh) 2012-05-11 2013-05-13 放射性药物络合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201380036807.4A Pending CN104619355A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CN201380036905.8A Pending CN104540530A (zh) 2012-05-11 2013-05-13 放射性药物络合物

Country Status (9)

Country Link
US (3) US20150104385A1 (enExample)
EP (3) EP2846843A1 (enExample)
JP (3) JP6211066B2 (enExample)
KR (3) KR20150092702A (enExample)
CN (3) CN104619355A (enExample)
CA (3) CA2873143A1 (enExample)
GB (1) GB201208309D0 (enExample)
HK (3) HK1206982A1 (enExample)
WO (3) WO2013167754A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056288A (zh) * 2018-11-20 2021-06-29 康奈尔大学 放射性核素的大环配合物及其在癌症的放射治疗中的应用
CN115916731A (zh) * 2020-01-23 2023-04-04 瑞德兰有限责任公司 用于制备定制的放射性同位素溶液的系统和方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008797A2 (en) 2006-07-10 2008-01-17 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10821195B2 (en) * 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
BR112018069485A2 (pt) * 2016-03-24 2019-07-30 Bayer As complexos radiofarmacêuticos
MA45225A (fr) 2016-06-10 2019-04-17 Bayer As Complexes radiopharmaceutiques
CA3054248A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
MX2020009472A (es) * 2018-03-14 2020-12-07 Us Health Receptores de antigenos quimericos anti-cd33 y sus usos.
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
USD885822S1 (en) 2018-12-14 2020-06-02 Whirlpool Corporation Food grinder
US20220125960A1 (en) 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
EP3927339A1 (en) 2019-02-22 2021-12-29 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
WO2021013978A1 (en) 2019-07-25 2021-01-28 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
EP4087621A4 (en) * 2020-01-10 2024-01-17 Fusion Pharmaceuticals Inc. MACROCYCLIC CHELATES AND USES THEREOF
EP4251179A4 (en) * 2020-11-30 2024-11-20 Simcere Innovation, Inc. Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003123A2 (en) * 2004-06-25 2006-01-12 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
WO2011098611A2 (en) * 2010-02-12 2011-08-18 Algeta As Alpha-emitting complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5624901A (en) * 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US7794691B2 (en) * 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
JP5352460B2 (ja) 2006-08-15 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ルミネッセント大環状ランタニド錯体
WO2011011592A1 (en) * 2009-07-22 2011-01-27 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
EP3263562A1 (en) * 2009-12-24 2018-01-03 Lumiphore, Inc. Radiopharmaceutical complexes
ES2496991T3 (es) * 2010-02-12 2014-09-22 Evonik Degussa Gmbh Composición cosmética que contiene éster parcial de poliglicerol
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003123A2 (en) * 2004-06-25 2006-01-12 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
WO2011098611A2 (en) * 2010-02-12 2011-08-18 Algeta As Alpha-emitting complexes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056288A (zh) * 2018-11-20 2021-06-29 康奈尔大学 放射性核素的大环配合物及其在癌症的放射治疗中的应用
CN115916731A (zh) * 2020-01-23 2023-04-04 瑞德兰有限责任公司 用于制备定制的放射性同位素溶液的系统和方法

Also Published As

Publication number Publication date
KR20150092702A (ko) 2015-08-13
US20150104385A1 (en) 2015-04-16
EP2846844A1 (en) 2015-03-18
WO2013167755A1 (en) 2013-11-14
JP6219372B2 (ja) 2017-10-25
US20150110817A1 (en) 2015-04-23
CN104540530A (zh) 2015-04-22
KR20150092700A (ko) 2015-08-13
HK1206982A1 (en) 2016-01-22
GB201208309D0 (en) 2012-06-27
JP6211066B2 (ja) 2017-10-11
CN104619355A (zh) 2015-05-13
HK1206981A1 (en) 2016-01-22
US20150147272A1 (en) 2015-05-28
JP2015517482A (ja) 2015-06-22
CA2873143A1 (en) 2013-11-14
HK1207307A1 (zh) 2016-01-29
KR20150092701A (ko) 2015-08-13
CA2873144A1 (en) 2013-11-14
CA2873144C (en) 2021-03-16
JP2015517483A (ja) 2015-06-22
US9827336B2 (en) 2017-11-28
WO2013167754A1 (en) 2013-11-14
WO2013167756A1 (en) 2013-11-14
CA2873142A1 (en) 2013-11-14
EP2846842A1 (en) 2015-03-18
JP2015523326A (ja) 2015-08-13
EP2846843A1 (en) 2015-03-18
EP2846844B1 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
CN104602716A (zh) 放射性药物络合物
US10682430B2 (en) Alpha-emitting complexes
AU2021202665B2 (en) Radio-pharmaceutical complexes
HK1239540A1 (en) Radio-pharmaceutical complexes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BAYER AG

Free format text: FORMER OWNER: ALGETA AS

Effective date: 20150710

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150710

Address after: Oslo, Norway

Applicant after: BAYER AG

Address before: Oslo, Norway

Applicant before: ALGETA A/S

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206982

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150506

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206982

Country of ref document: HK